MINI FUTURE SHORT - ORION B | Real-time Bid/Ask 05:17:53 31/05/2024 pm IST | ||
| 1.63 EUR / 1.64 EUR | +0.31% |
|
| Current month | -7.39% | ||
| 1 month | -7.39% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ORION OYJ
Latest news about ORION OYJ
More news
| Date | Price | Change |
|---|---|---|
| 31/24/31 | 1.65 | +1.23% |
| 30/24/30 | 1.63 | -2.98% |
| 29/24/29 | 1.68 | +5.66% |
| 28/24/28 | 1.59 | +1.27% |
| 27/24/27 | 1.57 | -3.68% |
Delayed Quote Börse Stuttgart
Last update May 31, 2024 at 12:58 pm IST
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | ORION OYJ |
| Issuer | Morgan Stanley |
| WKN | ME72W7 |
| ISIN | DE000ME72W72 |
| Date issued | 17/01/2024 |
| Strike | 53.51 € |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.04 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.15 € |
|---|---|
| Lowest since issue | 0.94 € |
| Spread | 0.01 € |
| Spread % | 0.61% |
Company Profile
Orion Oyj is Finland's leading pharmaceutical group. Net sales break down by family products and services as follows:
- generic, OTC and biosimilar drugs (43.4%);
- patented prescription products (41.7%): notably intended for treating dysfunctions of the nervous system, cardiovascular diseases, hormonal and urological treatments;
- animal health products (8.7%);
- pharmaceutical ingredients and outsourcing services (6.2%).
Net sales break down primarily by source of revenue between sales of products (86.9%) and royalties (10.4%).
Net sales are distributed geographically as follows: Finland (28%), Scandinavia (12%), Europe (30.8%), North America (14.7%) and other (14.5%).
Sector
-
Consensus: Orion Oyj
Sell
Buy
Mean consensus
HOLD
Number of Analysts
6
Last Close Price
36.97
EUR
Average target price
39
EUR
Spread / Average Target
+5.49%
- Stock Market
- Certificates
- Certificat
